The biggest names in cardiology tech gathered in New Orleans for the American College of Cardiology (ACC) Scientific Sessions ...
NEW ALBANY — Baptist Health Floyd recently completed its 500th Watchman procedure. The Watchman device is an alternative to ...
A new Watchman device at McLaren Port Huron offers eligible AFib patients an alternative to long‑term blood thinners to help ...
Boston Scientific (BSX) is down 35% but still growing fast with strong margins—see valuation, key catalysts (WATCHMAN, EP, ...
Boston presented the pair of trial readouts at the 2026 American College of Cardiology (ACC) conference in New Orleans.
Boston Scientific (BSX) stock tumbled 9% to two-year lows after Watchman trial data revealed stroke concerns and Raymond ...
CHAMPION-AF shows Boston Scientific's Watchman FLX as a safe, effective first-line option for stroke risk reduction in ...
Data for Boston Scientific’s Watchman FLX implant met the primary endpoint in a new study. The stock is falling anyway.
Investor's Business Daily on MSN
Boston Scientific just took a 9% header. Why analysts are still bullish
Boston Scientific stock tumbled Monday on mixed test results for its Watchman device in patients at risk of having a stroke.
Boston Scientific (BSX) stock plummeted 8% after Raymond James downgraded the company and lowered its price target to $88 on slowing growth in key segments.
In one of the largest studies of its kind, a trial of Boston Scientific’s small, permanent cardiac implant showed that it could potentially serve as an alternative to long-term blood thin | Boston ...
Boston Scientific Corp’s stock recently traded at $65.26, hovering near its 52-week low of $67.56, underscoring a challenging year for the medical device company with a market c ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results